15LBA High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients
Brandon W. Higgs(Parker Institute for Cancer Immunotherapy), K. Ranade, Chris Morehouse, Yu Yao(Qinghai University), Libing Shi(Sir Run Run Shaw Hospital), P.Z. Brohawn, Xin Jin, Wei-Shan Zhu, Marlon C. Rebelatto(AstraZeneca (Japan)), Paul B. Robbins(Pfizer (United States)), John A. Blake-Haskins(Inserm)
Cited by 30
Related Papers
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
CGCG clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2016|650
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
|Cell|2020|546
Clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2020|482
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
|Annals of the Rheumatic Diseases|2011|412